4,730 results on '"oxcarbazepine"'
Search Results
2. Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Author
-
Patient-Centered Outcomes Research Institute, Montana State University, National Alliance on Mental Illness Montana, CGStat LLC, Risk Benefit Statistics LLC, National Alliance on Mental Illness New Mexico, National Alliance on Mental Illness Westside Los Angeles, and Christophe Gerard Lambert, Associate Professor
- Published
- 2024
3. Anticonvulsants in the Treatment of Behavioral and Psychological Symptoms in Dementia: A Systematic Review.
- Author
-
Benjamin, Sophiya, Ho, Joanne Man-Wai, Tung, Jennifer, Dholakia, Saumil, An, Howard, Antoniou, Tony, Sanger, Stephanie, and Williams, John W.
- Abstract
• What is the primary question addressed by this study? What is the efficacy and safety of non-benzodiazepine anticonvulsants for treating behavioral and psychological symptoms of dementia (BPSD)? • What is the main finding of this study? Our systematic review of clinical trials found that non-benzodiazepine anticonvulsants (i.e., carbamazepine, oxcarbazepine, valproate preparations, topiramate) are unlikely to be effective in BPSD, and may be associated with a higher prevalence of adverse effects than comparator treatments. The quality of existing evidence is low. • What is the meaning of the finding? Existing evidence does not support the use of non-benzodiazepine anticonvulsants as treatment for BPSD. Behavioral and psychological symptoms of dementia (BPSD) are common and impart a significant burden to patients, caregivers, and the health system. However, there are few pharmacological options for treating BPSD. We conducted a systematic review of clinical trials examining the efficacy of anticonvulsants in BPSD. We searched five electronic databases through January 2023, for randomized controlled trials and systematic reviews evaluating the efficacy of non-benzodiazepine anticonvulsants for the treatment of BPSD. We used the Cochrane risk of bias tool to ascertain the risk of bias in included trials. Because statistical pooling of results using meta-analysis was not feasible, we synthesized findings using the Cochrane Synthesis Without Meta-analysis reporting guidelines. We identified 12 studies, including randomized controlled trials (RCTs) and 1 systematic review. Five RCTs evaluating valproic acid were synthesized by a recent Cochrane review which concluded that this drug is likely ineffective for BPSD. We extracted data from 6 trials involving 248 individuals comparing non-benzodiazepine anticonvulsants to either placebo or risperidone. Four trials (n = 97 participants) evaluated carbamazepine, only one of which demonstrated an improvement in the Brief Psychiatric Rating Scale measuring agitation, hostility, psychosis, and withdrawal/depression (effect size: 1.13; 95% confidence interval [CI]: 0.54–1.73) relative to placebo. Adverse effects were more common in patients receiving carbamazepine (20/27; 74%) relative to placebo (5/24; 21%). There is low quality evidence that oxcarbazepine is likely ineffective and that topiramate may be comparable to risperidone. Anticonvulsants are unlikely to be effective in BPSD, although the quality of existing evidence is low. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Development of a UPLC-MS/MS Method to Simultaneously Measure 13 Antiepileptic Drugs with Deuterated Internal Standards.
- Author
-
Jae Hyun Cha, Hyebin Choi, Jisook Yim, Keun Ju Kim, Minjeong Nam, Myung Hyun Nam, Chang Kyu Lee, Dae Won Kim, Yunjung Cho, and Seung Gyu Yun
- Subjects
ANTICONVULSANTS ,CARBAMAZEPINE ,PERAMPANEL ,DRUG monitoring ,TOPIRAMATE ,PREGABALIN ,LEVETIRACETAM - Abstract
Background: The goal of this study was to develop and validate a UPLC-MS/MS method for simultaneous measurement of 13 AEDs, including carbamazepine, oxcarbazepine, lamotrigine, levetiracetam, topiramate, primidone, zonisamide, gabapentin, lacosamide, perampanel, pregabalin, rufinamide, and vigabatrin, in whole blood samples. Methods: A UPLC-MS/MS method for simultaneous determination of 13 AEDs in whole blood was developed, and validation was conducted for accuracy, precision, limit of quantification (LOQ), matrix effect, and stability. Our method was compared to two different hospitals using UPLC-MS/MS. Results: All AEDs exhibited linearity across the AMR (analytical measurement range), with R² values ranging from 0.994 to 1.000. The imprecision and inaccuracy for low and high quality control (QC) levels were within an acceptable range, with the coefficient of variation (CV) < 15%. The LOQ was 0.62 μg/mL for carbamazepine, 1.61 μg/mL for oxcarbazepine, 1.30 μg/mL for lamotrigine, 13.20 μg/mL for levetiracetam, 1.26 μg/mL for topiramate, 1.01 μg/mL for primidone, 1.59 μg/mL for zonisamide, 1.09 μg/mL for lacosamide, 1.61 μg/mL for gabapentin, 0.50 μg/mL for pregabalin, 0.07 ng/mL for perampanel, 3.00 μg/mL for rufinamide, and 2.06 μg/mL for vigabatrin. All AEDs demonstrated acceptable assay parameters for carryover, stability, and matrix effects. Moreover, the assay showed satisfactory results compared to two different hospitals with a bias of less than 15%. Conclusions: We successfully developed and validated a fast and robust UPLC-MS/MS method for routine therapeutic drug monitoring of thirteen antiepileptic drugs simultaneously. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The use of an RP-HPLC-UV method for the analysis of oxcarbazepine in the presence of its preservatives; stability studies and application to human plasma samples.
- Author
-
Fouad, Ali, Abdelkhalek, Ahmed S., Elrefay, Hisham, Batakoushy, Hany A., and Soltan, Moustafa K.
- Subjects
DRUG monitoring ,DRUG analysis ,LIQUID chromatography ,THERAPEUTIC equivalency in drugs ,HIGH performance liquid chromatography ,POTASSIUM dihydrogen phosphate - Abstract
A simple, sensitive, selective, accurate and precise method was developed and fully validated for determination of oxcarbazepine (OXC) in presence of their preservatives and determination of oxcarbazepine (OXC) in human plasma. A reversed phase liquid chromatography (RP-HPLC) with UV detection techniques were applied for separation and quantification of studied drug OXC. Successful separation of the drug from methyl paraben (M.P.), propyl paraben (P.P.) and potassium sorbate (P.ST.) was achieved on a Kromasil C18 column (5 μm particle size, pore size 300 Å, l × I.D. 250 × 4.6 mm). The mobile phase that contain aqueous 0.05M potassium dihydrogen phosphate buffer (pH 7): acetonitrile, (50: 50, %v/v). The method was linear over concentration ranges 5.0–50 μg mL
−1 for OXC. Bioanalytical validation of the developed method was carried out according to US-FDA guidelines and revealed a good linear relations over a range of (5.0–50), (0.5–10), (0.05–0.15), and (1.0–10) μg mL−1 for OXC, M.P, P.P, and P.ST, respectively, with a correlation coefficient (R2) of more than 0.999. Limit of detection (LOD) were 1.15, 0.03, 0.01 and 0.04 μg mL−1 for OXC, M.P, P.P, and P.ST, respectively, Intra and inter-day precisions, calculated as percentage relative standard deviation (% RSD), were lower than 2.0%. The developed method can be applied for routine drug analysis, therapeutic drug monitoring and bioequivalence studies through the analysis of plasma samples taken from blood bank. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. 奥卡西平治疗妊娠期癫痫的安全性研究进展.
- Author
-
周善毛 and 王玉贤
- Abstract
Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
7. Medikamentöse Therapie der Trigeminusneuralgie: Die neue Leitlinie.
- Author
-
Ruscheweyh, Ruth, Gierthmühlen, Janne, Hedderich, Dennis M., Goßrau, Gudrun, and Leis, Stefan
- Abstract
Copyright of Der Schmerz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
8. The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
- Published
- 2023
9. The Role of EEG microstates in predicting oxcarbazepine treatment outcomes in patients with newly-diagnosed focal epilepsy.
- Author
-
Rong, Rong, Zhang, Runkai, Xu, Yun, Wang, Xiaoyun, Wang, Haixian, and Wang, Xiaoshan
- Abstract
• This pioneering study utilizes microstates, brief and global brain activity topographies, to predict Oxcarbazepine treatment outcomes in newly-diagnosed focal epilepsy patients through pre-medication Electroencephalography (EEG). • In the Not Seizure-Free (NSF) group, higher Microstate 1 (MS1) temporal parameters and increased transition probability to MS1 were observed compared to Seizure-Free (SF), suggesting MS1 as a potential biomarker for predicting Oxcarbazepine treatment outcomes. • By using extracted microstates features for prediction, the highest area under curve (0.95) was achieved by Support Vector Machine and Logistic Regression. Microstates represent the global and topographical distribution of electrical brain activity from scalp-recorded EEG. This study aims to explore EEG microstates of patients with focal epilepsy prior to medication, and employ extracted microstate metrics for predicting treatment outcomes with Oxcarbazepine monotherapy. This study involved 25 newly-diagnosed focal epilepsy patients (13 females), aged 12 to 68, with various etiologies. Patients were categorized into Non-Seizure-Free (NSF) and Seizure-Free (SF) groups according to their first follow-up outcomes. From pre-medication EEGs, four representative microstates were identified by using clustering. The temporal parameters and transition probabilities of microstates were extracted and analyzed to discern group differences. With generating sample method, Support Vector Machine (SVM), Logistic Regression (LR), and Naïve Bayes (NB) classifiers were employed for predicting treatment outcomes. In the NSF group, Microstate 1 (MS1) exhibited a significantly higher duration (mean±std. = 0.092±0.008 vs. 0.085±0.008, p = 0.047), occurrence (mean±std. = 2.587±0.334 vs. 2.260±0.278, p = 0.014), and coverage (mean±std. = 0.240±0.046 vs. 0.194±0.040, p = 0.014) compared to the SF group. Additionally, the transition probabilities from Microstate 2 (MS2) and Microstate 3 (MS3) to MS1 were increased. In MS2, the NSF group displayed a stronger correlation (mean±std. = 0.618±0.025 vs. 0.571±0.034, p < 0.001) and a higher global explained variance (mean±std. = 0.083±0.035 vs. 0.055±0.023, p = 0.027) than the SF group. Conversely, Microstate 4 (MS4) in the SF group demonstrated significantly greater coverage (mean±std. = 0.388±0.074 vs. 0.334±0.052, p = 0.046) and more frequent transitions from MS2 to MS4, indicating a distinct pattern. Temporal parameters contribute major predictive role in predicting treatment outcomes of Oxcarbazepine, with area under curves (AUCs) of 0.95, 0.70, and 0.86, achieved by LR, NB and SVM, respectively. This study underscores the potential of EEG microstates as predictive biomarkers for Oxcarbazepine treatment responses in newly-diagnosed focal epilepsy patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Formulation and Evaluation of Fast Dissolving Tablets of Oxcarbazepine Using Liquisolid Technology.
- Author
-
Mohana, Bindhu Booraguntae, Maddi, Eswar Gupta, and Dang, Raman
- Subjects
DRUG solubility testing ,DRUG solubility ,DIFFERENTIAL scanning calorimetry ,POLYETHYLENE glycol ,SILICA ,PROPYLENE glycols - Abstract
Background/Aim: The aim of the study was to improve the dissolution profiles of Oxcarbazepine (OXC) from its tablets. This study was done to evaluate the effects of different formulation variables, i.e. type of non-volatile liquid vehicles on oxcarbazepine dissolution rate from its tablets. Materials and Methods: The liquisolid tablets were formulated with three different liquid vehicles, namely Polyethylene glycol 200, Propylene glycol and 20% Tween 80 aqueous solution. Micro-crystalline cellulose was used as a carrier material, silicon dioxide as a coating material and sodium starch glycolate as super disintegrate. The empirical method introduced by Spireas and Bolton (1999) was applied strictly to calculate the amounts of coating and carrier materials required to prepare fast dissolving tablets of OXC using liquisolid technique. The tablets passed all the routine quality control tests prescribed by official books. In vitro drug dissolution testing of the liquisolid tablets were done and compared with commercial tablets in 1% SLS solution as dissolution media as per USFDA. Results: It was found that the dissolution rate of oxcarbazepine was highest from liquisolid tablets of oxcarbazepine formulated using PEG 200. Differential scanning calorimetry, PXRD and Fourier transform infrared evaluation of our best tablet Formulation (F2) indicated that there is no physico-chemical interaction between OXC and the excipients. Conclusion: In vitro dissolution testing, DSC, PXRD and FTIR studies confirmed F2 as the best formulation with respect to drug dissolution rate and revealed that there is no incompatibility between the drug and excipients used in the formulation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Chronic Treatment with Oxcarbazepine Attenuates Its Anticonvulsant Effect in the Maximal Electroshock Model in Mice.
- Author
-
Borowicz-Reutt, Kinga and Banach, Monika
- Subjects
- *
HIGH performance liquid chromatography , *LABORATORY mice , *LONG-term memory , *MOTOR ability , *PHENOBARBITAL , *ANTICONVULSANTS , *MEMORY disorders - Abstract
The objective of this study was to assess the impact of acute and chronic treatment with oxcarbazepine on its anticonvulsant activity, neurological adverse effects, and protective index in mice. Oxcarbazepine was administered in four protocols: once or twice daily for one week (7 × 1 or 7 × 2) and once or twice daily for two weeks (14 × 1 or 14 × 2). A single dose of the drug was employed as a control. The anticonvulsant effect was evaluated in the maximal electroshock test in mice. Motor and long-term memory impairment were assessed using the chimney test and the passive avoidance task, respectively. The concentrations of oxcarbazepine in the brain and plasma were determined via high-performance liquid chromatography. Two weeks of oxcarbazepine treatment resulted in a significant reduction in the anticonvulsant (in the 14 × 1; 14 × 2 protocols) and neurotoxic (in the 14 × 2 schedule) effects of this drug. In contrast, the protective index for oxcarbazepine in the 14 × 2 protocol was found to be lower than that calculated for the control. No significant deficits in memory or motor coordination were observed following repeated administration of oxcarbazepine. The plasma and brain concentrations of this anticonvulsant were found to be significantly higher in the one-week protocols. Chronic treatment with oxcarbazepine may result in the development of tolerance to its anticonvulsant and neurotoxic effects, which appears to be dependent on pharmacodynamic mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Population Pharmacokinetics of Antiepileptic in Pediatrics (EPIPOP)
- Published
- 2023
13. A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use.
- Author
-
Yeh, Paul, Spruyt, Karen, DelRosso, Lourdes, and Walters, Arthur
- Subjects
amantadine ,bupropion ,cannabis ,carbamazepine ,clonidine ,dipyridamole ,ketamine ,lamotrigine ,levetiracetam ,oxcarbazepine ,perampanel ,steroids ,topiramate ,valproic acid ,Humans ,Anticonvulsants ,Restless Legs Syndrome ,Carbamazepine ,Gabapentin ,Glutamates - Abstract
BACKGROUND: There are several well-known treatments for Restless Legs Syndrome (RLS), including dopamine agonists (pramipexole, ropinirole, rotigotine), anticonvulsants (gabapentin and its analogs, pregabalin), oral or intravenous iron, opioids and benzodiazepines. However, in clinical practice, treatment is sometimes limited due to incomplete response or side effects and it is necessary to be aware of other treatment options for RLS, which is the purpose of this review. METHODS: We performed a narrative review detailing all of the lesser known pharmacological treatment literature on RLS. The review purposefully excludes well-established, well-known treatments for RLS which are widely accepted as treatments for RLS in evidence-based reviews. We also have emphasized the pathogenetic implications for RLS of the successful use of these lesser known agents. RESULTS: Alternative pharmacological agents include clonidine which reduces adrenergic transmission, adenosinergic agents such as dipyridamole, glutamate AMPA receptor blocking agents such as perampanel, glutamate NMDA receptor blocking agents such as amantadine and ketamine, various anticonvulsants (carbamazepine/oxcarbazepine, lamotrigine, topiramate, valproic acid, levetiracetam), anti-inflammatory agents such as steroids, as well as cannabis. Bupropion is also a good choice for the treatment of co-existent depression in RLS because of its pro-dopaminergic properties. DISCUSSION: Clinicians should first follow evidence-based review recommendations for the treatment of RLS but when the clinical response is either incomplete or side effects are intolerable other options can be considered. We neither recommend nor discourage the use of these options, but leave it up to the clinician to make their own choices based upon the benefit and side effect profiles of each medication.
- Published
- 2023
14. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review.
- Author
-
Naderi, Yeganeh, Rad, Maryam, Sadatmoosavi, Ali, Khaleghi, Elham, Khorrami, Zahra, Chamani, Goli, and Shabani, Mohammad
- Subjects
BOTULINUM A toxins ,TRIGEMINAL neuralgia ,NEURALGIA ,CARBAMAZEPINE ,TERMINATION of treatment - Abstract
Objectives: This review aimed to compare the effectiveness of three treatments: BTX A, CBZ, and OXB, in managing trigeminal neuralgia (TN). Material and Methods: We conducted a thorough search for research articles related to our issue using specific keywords on several databases, including Cochrane Central Register of Controlled Trials, Science Direct, Scopus, PubMed, Elsevier, Springer Journals, Ovid Medline, EBSCO, and Web of Science. Our focus was on publications from 1965 to 2023. Results: We retrieved 46 articles from the search and reviewed them carefully. Out of these, we selected 29 articles that met the inclusion criteria. Among the selected articles, 11 investigated the effects of CBZ and OXB, while 18 explored the impact of BTX A on the improvement of TN symptoms. The response rate ranged between 56% and 90.5% for CBZ and between 90.9% and 94% for OXB. The response rate for BTX A ranged between 51.4% and 100%. All these three treatments had a remarkable effect on the improvement of TN. Importantly, findings highlighted that side effects of CBZ and OXB could lead to treatment discontinuation in some cases, whereas BTX A's side effects have been minimal and less frequent. Conclusions: Consequently, BTX A emerges as a promising alternative for TN treatment. However, additional clinical trials are necessary to validate this finding, and further research is required to establish a standardized protocol for administering BTX A in TN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02.
- Author
-
Stancil, Stephani L., Sandritter, Tracy, and Strawn, Jeffrey R.
- Subjects
- *
PHARMACOGENOMICS , *DRUG interactions , *TEENAGERS , *GENETIC testing , *GENETIC variation - Abstract
Background: Oxcarbazepine is thought to be better-tolerated and less susceptible to drug–drug interactions than its predecessor, carbamazepine. Genetic testing for HLA-B*15:02 is recommended in specific populations to identify those at high risk of severe hypersensitivity reactions; however, other pharmacologic and pharmacogenetic factors that can impact drug disposition may be involved. Methods: We present a case of an 8-year-old boy treated with oxcarbazepine who developed drug reaction with eosinophilia and systemic symptoms (DRESS) with Stevens–Johnsons syndrome overlap and was negative for HLA-B*15:02. We review the extant literature related to oxcarbazepine disposition, and potential pharmacogenetic variants in aldoketoreductase 1C (AKR1C)2–4 that may contribute to this risk. Results: Genetic variability in oxcarbazepine disposition pathways may contribute to tolerability and toxicity, including the development of hypersensitivity reactions. Conclusions: While preemptive genetic testing for HLA-B*15:02 in individuals of Asian ancestry is recommended to prevent severe hypersensitivity reactions to oxcarbazepine, oxcarbazepine concentrations and AKR1C variation may contribute to the risk of severe adverse reactions. We provide recommendations for future study to elucidate whether these individual factors are important for reducing the risk of severe adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review
- Author
-
Brandon Brown, Brian Tong, Luke Pro, and Suzanna Kitten
- Subjects
Major depressive disorder ,Bipolar disorder ,Mood disorder ,Mood stabilizer ,Oxcarbazepine ,Depressive disorder ,Psychiatry ,RC435-571 - Abstract
Oxcarbazepine is often utilized off-label for bipolar and depressive disorders in outpatient settings despite limited evidence. We performed a retrospective chart review on 38 adult outpatients diagnosed with bipolar and depressive disorders (ICD-10 codes F30-39), treated with oxcarbazepine by psychiatrists and psychiatric nurse practitioners between 2015 and 2021. Primary outcomes were Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores, assigned retrospectively from clinical documentation. Patients were predominantly female (70%), aged 20–76 (mean 36), with a mean of 1.8 DSM diagnoses (range 1–4) and 1.7 (range 0–5) concurrent psychotropic medications. A starting mean oxcarbazepine dose of 489 mg/day, titrated to a mean final dose of 663 mg/day, was associated with a CGI-I of 2.5 [2.25, 2.75] and a pre-to-post treatment decrease in CGI-S from 3.4 to 2.4. Overall response and remission rates were 52% and 29%, respectively. Limitations of this study include potential sample bias, documentation bias and rater bias among other limitations inherent to retrospective study designs.
- Published
- 2024
- Full Text
- View/download PDF
17. Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study
- Author
-
Monique Ribeiro, Physician
- Published
- 2023
18. Effect of anti-epileptic drugs usage on thyroid profile in Egyptian epileptic children
- Author
-
Amira Rafik, Nahed Salah El-Din, Naglaa Mohamed El Khayat, Maha Nada, and Eman Mones Abushady
- Subjects
Children with epilepsy ,Thyroid profile ,Dyslipidemia ,Oxcarbazepine ,Carbamazepine ,Levetiracetam ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Background The long-term use of anti-seizure medications (ASMs) adversely affects thyroid, lipid profile and other metabolic functions. Subclinical hypothyroidism and alterations in thyroid hormone serum levels are reported with older ASMs in adults with limited and conflicting data of the influence of ASMs especially newer one on thyroid function in children. This study aimed to investigate the effects of conventional and newer ASMs whether mono or polytherapy on thyroid profile in children with epilepsy and its impact on lipid profile and metabolic functions. Results This study included 155 children with epilepsy (76 on monotherapy and 79 on polytherapy) with mean age of 9.677 ± 3.981 years (54.84% euthyroid, 31.61% hypothyroid, 9.68% subclinical hyperthyroid and 3.87% subclinical hypothyroid) and 78 healthy controls. Children with epilepsy whether on monotherapy or on polytherapy had a statistically significant thyroid profile abnormalities (hypothyroidism, sub-clinical hypothyroidism or sub-clinical hyperthyroidism), dyslipidemia, delayed growth and increase in DBP compared to control group. There was a statistically significant positive correlation between hypothyroidism and dyslipidemia as well as between hypothyroidism and delayed growth and increase in DBP. There was no statistically significant difference between polytherapy and monotherapy regarding thyroid and lipid parameters but children with epilepsy on polytherapy were associated with more statistically significant delay in growth and increase in DBP compared to monotherapy group. Carbamazepine had a statistically significant association with hypothyroidism, increase in DBP and higher total and LDL-cholesterol. Valproic acid had a statistically significant association with sub-clinical hypothyroidism with a positive dose correlation. Levetiracetam (LEV) was associated with a statistically significant lower HDL-cholesterol. All echocardiography data showed no abnormality. Conclusion ASMs whether older or newer generations can affect thyroid and lipid profile differently through different mechanisms that are dose and duration dependent regardless of the seizure type and age of the patient. ASMs mainly conventional ones are associated with hypothyroidism, sub-clinical hypothyroidism, sub-clinical hyperthyroidism, dyslipidemia and consequently delayed growth and diastolic blood pressure abnormalities.
- Published
- 2024
- Full Text
- View/download PDF
19. The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
- Author
-
Roro Rukmi Windi Perdani, Principal investigator
- Published
- 2023
20. Genetic and phenotypic analyses of PRRT2 positive and negative paroxysmal kinesigenic dyskinesia.
- Author
-
Zhang, Yingying, Ren, Jiechuan, Yang, Tianhua, Xiong, Weixi, Qin, Linyuan, An, Dongmei, Hu, Fayun, and Zhou, Dong
- Subjects
PHENOTYPES ,PAROXYSMAL hemoglobinuria ,DYSKINESIAS ,EXOMES ,GENEALOGY - Abstract
Background: Paroxysmal kinesigenic dyskinesia (PKD) is a rare neurological disorder, characterized by attacks of involuntary movements triggered by sudden action. Variants in proline-rich transmembrane protein 2 (PRRT2) are the most common genetic cause of PKD. Objective: The objective was to investigate the clinical and genetic characteristics of PKD and to establish genotype–phenotype correlations. Methods: We enrolled 219 PKD patients, documented their clinical information and performed PRRT2 screening using Sanger sequencing. Whole exome sequencing was performed on 49 PKD probands without PRRT2 variants. Genotype–phenotype correlation analyses were conducted on the probands. Results: Among 219 PKD patients (99 cases from 39 families and 120 sporadic cases), 16 PRRT2 variants were identified. Nine variants (c.879+4A>G, c.879+5G>A, c.856G>A, c.955G>T, c.884G>C, c.649C>T, c.649dupC, c.649delC and c.696_697delCA) were previously known, while seven were novel (c.367_403del, c.347_348delAA, c.835C>T, c.116dupC, c.837_838insC, c.916_937del and c.902G>A). The mean interval from onset to diagnosis was 7.94 years. Compared to patients without PRRT2 variants, patients with the variants were more likely to have a positive family history, an earlier age of onset and a higher prevalence of falls during pre-treatment attacks (27.14% versus 8.99%, respectively). Patients with truncated PRRT2 variants tend to have bilateral attacks. We identified two transmembrane protein 151A (TMEM151A) variants including a novel variant (c.368G>C) and a reported variant (c.203C>T) in two PRRT2-negative probands with PKD. Conclusion: These findings provide insights on the clinical characteristics, diagnostic timeline and treatment response of PKD patients. PKD patients with truncated PRRT2 variants may tend to have more severe paroxysmal symptoms. This study expands the spectrum of PRRT2 and TMEM151A variants. Carbamazepine and oxcarbazepine are both used as a first-line treatment choice for PKD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. 丙戊酸钠联合奥卡西平治疗小儿癫痫的疗效 及对患儿脑电图、认知功能和血清神经因子的影响.
- Author
-
刘 幸, 王 敏, 张 蕾, 王婉娟, and 刘晓庆
- Abstract
Objective: To evaluate the efficacy of sodium valproate combined with oxcarbazepine in the treatment of pediatric epilepsy and its effects on electroencephalogram, cognitive function and serum neurotrophic factors. Methods: 104 children with epilepsy from January 2019 to December 2022 were selected and divided into a monotherapy group (sodium valproate treatment) and a combination group (sodium valproate + oxcarbazepine treatment) based on different treatment methods, with 52 cases in each group. Evaluate and compare the clinical efficacy, EEG, cognitive function, serum neurofactors, and other indicators between the two groups. Results: After treatment, the frequency and duration of seizures in the combination group were lower than those in the monotherapy group (P<0.05), and the EEG showed a lower epileptiform discharge rate and total abnormality compared to the monotherapy group (P<0.05). The total effective rate of the combination group was 94.23%, higher than 71.15% in the monotherapy group (P<0.05). After treatment, the scores of VIQ, PIQ, and FIQ on the WISC-CR scale in both groups were higher than before treatment (P<0.05), while the increase in the combination group was greater than that in the monotherapy group (P<0.05). There was no difference in serum BDNF, NSE and S-100β between the two groups before treatment (P>0.05), but after treatment, the serum BDNF level in the combination group were higher than that in the monotherapy group, NSE and S-100β levels were lower than those in the monotherapy group (P<0.05). There was no difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Valproate combined with oxcarbamazepine is effective in pediatric epilepsy, which can effectively relieve clinical symptoms, control abnormal brain discharge, improve cognitive function, regulate the level of serum nerve factors, and have good safety. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Effect of anti-epileptic drugs usage on thyroid profile in Egyptian epileptic children.
- Author
-
Rafik, Amira, El-Din, Nahed Salah, El Khayat, Naglaa Mohamed, Nada, Maha, and Abushady, Eman Mones
- Subjects
- *
CHILDREN with epilepsy , *ANTICONVULSANTS , *DIASTOLIC blood pressure , *THYROID gland , *VALPROIC acid - Abstract
Background: The long-term use of anti-seizure medications (ASMs) adversely affects thyroid, lipid profile and other metabolic functions. Subclinical hypothyroidism and alterations in thyroid hormone serum levels are reported with older ASMs in adults with limited and conflicting data of the influence of ASMs especially newer one on thyroid function in children. This study aimed to investigate the effects of conventional and newer ASMs whether mono or polytherapy on thyroid profile in children with epilepsy and its impact on lipid profile and metabolic functions. Results: This study included 155 children with epilepsy (76 on monotherapy and 79 on polytherapy) with mean age of 9.677 ± 3.981 years (54.84% euthyroid, 31.61% hypothyroid, 9.68% subclinical hyperthyroid and 3.87% subclinical hypothyroid) and 78 healthy controls. Children with epilepsy whether on monotherapy or on polytherapy had a statistically significant thyroid profile abnormalities (hypothyroidism, sub-clinical hypothyroidism or sub-clinical hyperthyroidism), dyslipidemia, delayed growth and increase in DBP compared to control group. There was a statistically significant positive correlation between hypothyroidism and dyslipidemia as well as between hypothyroidism and delayed growth and increase in DBP. There was no statistically significant difference between polytherapy and monotherapy regarding thyroid and lipid parameters but children with epilepsy on polytherapy were associated with more statistically significant delay in growth and increase in DBP compared to monotherapy group. Carbamazepine had a statistically significant association with hypothyroidism, increase in DBP and higher total and LDL-cholesterol. Valproic acid had a statistically significant association with sub-clinical hypothyroidism with a positive dose correlation. Levetiracetam (LEV) was associated with a statistically significant lower HDL-cholesterol. All echocardiography data showed no abnormality. Conclusion: ASMs whether older or newer generations can affect thyroid and lipid profile differently through different mechanisms that are dose and duration dependent regardless of the seizure type and age of the patient. ASMs mainly conventional ones are associated with hypothyroidism, sub-clinical hypothyroidism, sub-clinical hyperthyroidism, dyslipidemia and consequently delayed growth and diastolic blood pressure abnormalities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Potential impact of mesenchymal stem cells on nephrotoxicity induced by gamma irradiation and antiepileptic drugs cotherapy in rats.
- Author
-
Gharib, Ola A., Fahmy, Hanan A., Mohamed, Marwa A., and Rashed, Laila A.
- Subjects
- *
MESENCHYMAL stem cells , *TRANSFORMING growth factors-beta , *ANTICONVULSANTS , *NEPHROTOXICOLOGY , *STEM cell treatment - Abstract
The goal of this study was to assess the influence of bone marrow‐derived mesenchymal stem cells (BM‐MSCs) on the nephrotoxicity induced by fractionated doses of gamma irradiation (Rad) and the cotherapy of levetiracetam and oxcarbazepine in male rats. Adult rats were randomly divided into four groups. Group I: Control, Group II: antiepileptic drugs (AEDs), Group III: AEDs +Rad and Group IV: AEDs + Rad + MSCs. Rats treated with AEDs and exposed to fractionated doses of γ‐irradiation displayed a discernible increase in serum urea, creatinine, kidney injury marker, kidney malondialdehyde, transforming growth factor beta (TGF‐β) and the relative expression of Smad3 along with a decrease in the relative expression of Smad7 and glutathione level. Alternatively, groups treated with BM‐MSCs with AEDs and Rad showed a substantial modification in the majority of the evaluated parameters and looked to be successful in reducing the hazards of the combination therapy of AEDs and radiation. The reno‐histopathological study supports the biochemical analysis. In conclusion, BM‐MSCs exhibited therapeutic potential against nephrotoxicity induced by fractionated doses of γ‐irradiation and AEDs. The outcome was brought about by the downregulation of the TGF‐β/Smad pathway. BM‐MSCs might be suggested as a valuable therapeutic strategy to overcome kidney injury induced by gamma irradiation during AEDs cotherapy. Significance statement: This work concerns the effect of stem cell treatment to eliminate the renal injury induced by gamma irradiation during antiepileptic drug cotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Método neutrosófico para el diagnóstico adecuado de la Neuralgia Trigeminal.
- Author
-
Acosta Guamán, Marilyn Gabriela, Trávez Corrales, Lady Mariela, Sánchez Sánchez, Javier Estuardo, and Romero Fernández, Ariel José
- Abstract
Copyright of Neutrosophic Computing & Machine Learning is the property of Multimedia Larga and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
25. Exploring the Spectrum of RHOBTB2 Variants Associated with Developmental Encephalopathy 64: A Case Series and Literature Review.
- Author
-
de Pedro Baena, Sonia, Sariego Jamardo, Andrea, Castro, Pedro, López González, Francisco Javier, Sánchez Carpintero, Rocío, Cerisola, Alfredo, Troncoso, Mónica, Witting, Scarlet, Barrios, Andrés, Fons, Carmen, López Pisón, Javier, and Ortigoza‐Escobar, Juan Darío
- Subjects
- *
LITERATURE reviews , *MOVEMENT disorders , *EPILEPSY , *BRAIN diseases , *MAGNETIC resonance imaging , *FOCAL dystonia , *CEREBRAL atrophy - Abstract
Background: Rho‐related BTB domain‐containing protein 2 (RHOBTB2) is a protein that interacts with cullin‐3, a crucial E3 ubiquitin ligase for mitotic cell division. RHOBTB2 has been linked to early infantile epileptic encephalopathy, autosomal dominant type 64 (OMIM618004), in 34 reported patients. Methods: We present a case series of seven patients with RHOBTB2‐related disorders (RHOBTB2‐RD), including a description of a novel heterozygous variant. We also reviewed previously published cases of RHOBTB2‐RD. Results: The seven patients had ages ranging from 2 years and 8 months to 26 years, and all had experienced seizures before the age of one (onset, 4–12 months, median, 4 months), including various types of seizures. All patients in this cohort also had a movement disorder (onset, 0.3–14 years, median, 1.5 years). Six of seven had a baseline movement disorder, and one of seven only had paroxysmal dystonia. Stereotypies were noted in four of six, choreodystonia in three of six, and ataxia in one case with multiple movement phenotypes at baseline. Paroxysmal movement disorders were observed in six of seven patients for whom carbamazepine or oxcarbazepine treatment was effective in controlling acute or paroxysmal movement disorders. Four patients had acute encephalopathic episodes at ages 4 (one patient) and 6 (three patients), which improved following treatment with methylprednisolone. Magnetic resonance imaging scans revealed transient fluid‐attenuated inversion recovery abnormalities during these episodes, as well as myelination delay, thin corpus callosum, and brain atrophy. One patient had a novel RHOBTB2 variant (c.359G>A/p.Gly120Glu). Conclusion: RHOBTB2‐RD is characterized by developmental delay or intellectual disability, early‐onset seizures, baseline movement disorders, acute or paroxysmal motor phenomena, acquired microcephaly, and episodes of acute encephalopathy. Early onsets of focal dystonia, acute encephalopathic episodes, episodes of tongue protrusion, or peripheral vasomotor disturbances are important diagnostic clues. Treatment with carbamazepine or oxcarbazepine was found to be effective in controlling acute or paroxysmal movement disorders. Our study highlights the clinical features and treatment response of RHOBTB2‐RD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis
- Author
-
Yuanyuan Liu, Yanxu Wang, Xingzhou Li, and Xiaomin Wu
- Subjects
levetiracetam ,oxcarbazepine ,monotherapy ,children with epilepsy ,meta-analysis ,Pediatrics ,RJ1-570 - Abstract
BackgroundLevetiracetam (LEV) and oxcarbazepine (OXC) are new antiseizure medications (ASMs). In recent years, OXC monotherapy is widely used in children with epilepsy; however, no consensus exists on applying LEV monotherapy among children with epilepsy.ObjectiveThe present work focused on comparing the efficacy and safety of LEV and OXC monotherapy in treating children with epilepsy.MethodsWe conducted a comprehensive search across multiple databases including PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang Database, VIP, and China Biology Medicine disc, covering studies from inception to August 26, 2023. We included randomized controlled trials (RCTs) and cohort studies evaluating the efficacy and safety of LEV and OXC monotherapy for treating epilepsy in children. We utilized Cochrane Risk of Bias Tool in RevMan 5.3 software for assessing included RCTs quality. In addition, included cohort studies quality was determined using Newcastle-Ottawa Scale (NOS). A random-effects model was utilized to summarize the results.ResultsThis meta-analysis included altogether 14 studies, including 893 children with epilepsy. LEV and OXC monotherapy was not statistical different among children with epilepsy in seizure-free rate (relative risk [RR] = 1.010, 95% confidence interval [CI] [0.822, 1.242], P > 0.05) and seizure frequency decrease of ≥50% compared with baseline [RR = 0.938, 95% CI (0.676, 1.301), P > 0.05]. Differences in total adverse reaction rate [RR = 1.113, 95% CI (0.710, 1.744), P > 0.05] and failure rate because of serious adverse reaction [RR = 1.001, 95% CI (0.349, 2.871), P > 0.05] were not statistical different between LEV and OXC treatments among children with epilepsy. However, the effects of OXC monotherapy on thyroid among children with epilepsy was statistically correlated than that of LEV (thyroid stimulating hormone: standardized mean difference [SMD] = −0.144, 95% CI [−0.613, 0.325], P > 0.05; free thyroxine: SMD = 1.663, 95% CI [0.179, 3.147], P
- Published
- 2024
- Full Text
- View/download PDF
27. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review
- Author
-
Yeganeh Naderi, Maryam Rad, Ali Sadatmoosavi, Elham Khaleghi, Zahra Khorrami, Goli Chamani, and Mohammad Shabani
- Subjects
botulinum toxin type A ,carbamazepine ,oxcarbazepine ,trigeminal neuralgia ,Dentistry ,RK1-715 - Abstract
Abstract Objectives This review aimed to compare the effectiveness of three treatments: BTX A, CBZ, and OXB, in managing trigeminal neuralgia (TN). Material and Methods We conducted a thorough search for research articles related to our issue using specific keywords on several databases, including Cochrane Central Register of Controlled Trials, Science Direct, Scopus, PubMed, Elsevier, Springer Journals, Ovid Medline, EBSCO, and Web of Science. Our focus was on publications from 1965 to 2023. Results We retrieved 46 articles from the search and reviewed them carefully. Out of these, we selected 29 articles that met the inclusion criteria. Among the selected articles, 11 investigated the effects of CBZ and OXB, while 18 explored the impact of BTX A on the improvement of TN symptoms. The response rate ranged between 56% and 90.5% for CBZ and between 90.9% and 94% for OXB. The response rate for BTX A ranged between 51.4% and 100%. All these three treatments had a remarkable effect on the improvement of TN. Importantly, findings highlighted that side effects of CBZ and OXB could lead to treatment discontinuation in some cases, whereas BTX A's side effects have been minimal and less frequent. Conclusions Consequently, BTX A emerges as a promising alternative for TN treatment. However, additional clinical trials are necessary to validate this finding, and further research is required to establish a standardized protocol for administering BTX A in TN.
- Published
- 2024
- Full Text
- View/download PDF
28. Prescribed antiseizure medication doses and their relation to defined daily doses for achieving seizure freedom in newly diagnosed patients with epilepsy
- Author
-
Hire Hersi, Jani Raitanen, Jukka T. Saarinen, and Jukka Peltola
- Subjects
antiseizure medication ,defined daily dose ,newly diagnosed epilepsy ,oxcarbazepine ,seizure freedom ,treatment outcomes ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Objectives To investigate the antiseizure medication (ASM) doses required to achieve seizure freedom and their correlation with the World Health Organization's defined daily doses (DDDs) in patients aged 16 years or older with newly diagnosed epilepsy. Methods The study included 459 patients with a validated diagnosis of new‐onset epilepsy. Patient records were retrospectively analyzed to determine the ASM doses in patients with or without seizure freedom during follow‐up. The DDD of the relevant ASM was then retrieved. Results The seizure‐freedom rate with first and subsequent ASMs was 88% (404/459 patients) during the follow‐up. The mean prescribed doses (PDDs) and PDD/DDD ratio of the most commonly used ASMs, ie, oxcarbazepine (OXC), carbamazepine (CBZ), and valproic acid (VPA), differed significantly between seizure‐free and non‐seizure‐free status (992 mg and 0.99 vs 1132 mg and 1.13; 547 mg and 0.55 vs 659 mg and 0.66; and 953 mg and 0.64 vs 1260 mg and 0.84, respectively). The effect of the OXC dose as the first failed ASM on the possibility of achieving seizure freedom was significant (Fisher's exact test, p = 0.002). Thirty‐four of 43 patients (79%) in which an OXC dose of ≤900 mg failed became seizure‐free, as compared with 24 of 54 patients (44%) with a failed OXC dose >900 mg. Significance The present study provides new insights into the doses of the commonly used ASMs such as OXC, CBZ, and VPA that can lead to seizure freedom as monotherapy or as combination therapy. The higher PDD/DDD ratio of OXC (0.99) than that of CBZ or VPA renders a generalized PDD/DDD comparison highly problematic.
- Published
- 2023
- Full Text
- View/download PDF
29. Effect of Sodium Valproate, Oxcarbazepine and Levetiracetam on the Development of Different Functional Areas in Children with Epilepsy by Griffiths Development Scales-Chinese Edition
- Author
-
BAI Yanmin, DU Kaixian, CHEN Hao, JIA Tianming, GONG Huan, YU Shengyuan, LI Lin, GUAN Jing, ZHU Yingying
- Subjects
epilepsy ,focal epilepsy ,sodium valproate ,oxcarbazepine ,levetiracetam ,griffiths development scales ,functional areas ,Medicine - Abstract
Background Epilepsy is a chronic episodic brain disorder with a high incidence and can seriously affect the quality of life of the patients. Therefore, timely treatment to control seizures is particularly important. Numerous studies have shown the effect of antiepileptic drugs on cognition, but there are few studies on the effects of different functional areas in children. Objective To explore the effects of sodium valproate (VPA) , oxcarbazepine (OXC) and levetiracetam (LEV) on the development of different functional areas in children with focal epilepsy by Griffiths Development Scales-Chinese Edition (GDS-C) . Methods A total of 83 children with focal epilepsy who attended in outpatient and ward of the Department of Pediatric Neurology of the Third Affiliated Hospital of Zhengzhou University for the first time from January 2021 to April 2022 were selected, and randomly divided into VPA group (n=27) , OXC group (n=28) and LEV group (n=28) according to the random number table method, 30 healthy children who were examined during the same period were selected as the control group. The changes of EEG interictal epileptiform activity (IEA) before and after 6 months of treatment were recorded and the clinical effect was evaluated according to seizure frequency, the GDS-C was used to evaluate the development quotient of each functional area in the children. Results The total clinical effective rates of VPA group, OXC group and LEV group were 92.6%, 89.3% and 92.9%, with no significant difference among the three groups (χ2=0.418, P=1.000) . The total EEG IEA effective rate of the VPA group, OXC group and LEV group were 88.9%, 57.1% and 89.3%, with significant differences among the three groups (χ2=11.152, P=0.004) ; the total effective rate of EEG IEA in OXC group was lower than that in VPA group and LEV group (P
- Published
- 2023
- Full Text
- View/download PDF
30. Chronic Treatment with Oxcarbazepine Attenuates Its Anticonvulsant Effect in the Maximal Electroshock Model in Mice
- Author
-
Kinga Borowicz-Reutt and Monika Banach
- Subjects
oxcarbazepine ,antiepileptic drugs ,chronic treatment ,epilepsy ,maximal electroshock-induced seizures ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The objective of this study was to assess the impact of acute and chronic treatment with oxcarbazepine on its anticonvulsant activity, neurological adverse effects, and protective index in mice. Oxcarbazepine was administered in four protocols: once or twice daily for one week (7 × 1 or 7 × 2) and once or twice daily for two weeks (14 × 1 or 14 × 2). A single dose of the drug was employed as a control. The anticonvulsant effect was evaluated in the maximal electroshock test in mice. Motor and long-term memory impairment were assessed using the chimney test and the passive avoidance task, respectively. The concentrations of oxcarbazepine in the brain and plasma were determined via high-performance liquid chromatography. Two weeks of oxcarbazepine treatment resulted in a significant reduction in the anticonvulsant (in the 14 × 1; 14 × 2 protocols) and neurotoxic (in the 14 × 2 schedule) effects of this drug. In contrast, the protective index for oxcarbazepine in the 14 × 2 protocol was found to be lower than that calculated for the control. No significant deficits in memory or motor coordination were observed following repeated administration of oxcarbazepine. The plasma and brain concentrations of this anticonvulsant were found to be significantly higher in the one-week protocols. Chronic treatment with oxcarbazepine may result in the development of tolerance to its anticonvulsant and neurotoxic effects, which appears to be dependent on pharmacodynamic mechanisms.
- Published
- 2024
- Full Text
- View/download PDF
31. Pharmacological Treatment of Trigeminal Neuralgias
- Author
-
Sindou, Marc, Brinzeu, Andrei, Sindou, Marc, and Brinzeu, Andrei
- Published
- 2023
- Full Text
- View/download PDF
32. Association of oxcarbazepine concentration with seizure frequency in pregnant women with epilepsy
- Author
-
Lin-yan Wei, Zheng-yan-ran Xu, Zhen-zhen Lai, Na Dong, Yi-wen Sang, and Yi Guo
- Subjects
Oxcarbazepine ,Pregnancy ,Women with epilepsy ,Therapeutic drug monitoring ,Ratio of target concentration ,Neurology. Diseases of the nervous system ,RC346-429 ,Neurophysiology and neuropsychology ,QP351-495 - Abstract
The management of epilepsy during pregnancy presents particular challenges for neurologists worldwide. Currently, there are no clear recommendations for oxcarbazepine (OXC) specific target concentration during pregnancy. We conducted this retrospective observational cohort study on pregnant women with epilepsy (WWE) who received OXC monotherapy or polytherapy, at the epilepsy outpatient clinic of a tertiary hospital in eastern China. Sixteen pregnancies of 16 WWE were split into the seizure-free group or the non-seizure-free group, according to whether they had been seizure free for more than one year prior to conception or not. There was a significantly decrease in OXC concentration throughout pregnancy, as indicated by the concentration/dose ratio and the ratio of target concentration (RTC). The second trimester of pregnancy was the period when seizure deterioration occurred the most, particularly in the non-seizure-free group. Lower RTC_OXC was identified to be a risk factor for increasing seizure frequency in both the total group and the non-seizure-free group in both univariate and multivariate analysis, with a threshold of 0.575 for differentiating patients at high-risk and low-risk for seizure deterioration. In conclusion, this study suggested an OXC concentration threshold of 0.575 during pregnancy for assisting neurologists in OXC drug monitoring and dose adaptation.
- Published
- 2024
- Full Text
- View/download PDF
33. Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy.
- Author
-
Jia-Qin Yi, Sheng Huang, Miao-Juan Wu, Jie-Hui Ma, Li-Juan Huang, Song Liang, and Dan Sun
- Subjects
PARTIAL epilepsy ,PERAMPANEL ,CHILDREN with epilepsy ,CHILDREN'S hospitals ,TEENAGERS ,REFUGEE children - Abstract
Objective: This study aims to compare the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children with focal epilepsy (FE). Methods: This is an ambispective, single-center, non-inferiority study comparing the effectiveness and safety of perampanel (PER) monotherapy and oxcarbazepine (OXC) monotherapy in children with newly diagnosed FE. The primary endpoint was a six-month seizure freedom rate. The secondary endpoints included retention, responder, and seizure freedom rates at 3, 6, and 12 months, respectively. Adverse events (AEs) were also recorded for both groups. Results: One hundred and thirty children and adolescents aged from 4 to 18years newly diagnosed with FE between May 2020 and November 2022 in Wuhan Children's Hospital were included. There were 71 patients in the PER group and 59 patients in the OXC group. In the per protocol set (PPS), 50 (78.1%) in the PER group and 43 (78.2%) in the OXC group completed six months of treatment without seizures. The lower 95% CI (66.0%--87.5%) limit of PER was higher than the non-inferiority margin of 62.4% (80% of the 6-month seizure freedom rate in the OXC group); PER was non-inferior to OXC. The 3-month and 12-month seizure freedom rates were 77.1% and 82.9% for the PER group, respectively, while they were 80.4% and 75.8% for the OXC group. There were no serious adverse events in both groups. Conclusion: PER showed comparable effectiveness and safety compared with OXC in children with newly diagnosed focal epilepsy, which might be an effective and safe treatment for children and adolescents with newly diagnosed FE. Clinical Trial Registration: Identifier ChiCTR2300074696 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Population pharmacokinetics of topiramate in Chinese children with epilepsy.
- Author
-
Wei, Shifeng, Li, Xingmeng, Zhang, Qiang, Wu, Han, Wu, Yun, Zhao, Zhigang, Mei, Shenghui, and Feng, Weixing
- Subjects
- *
DRUG efficacy , *BODY weight , *EPILEPSY , *BLOOD plasma , *GENETIC polymorphisms , *GOODNESS-of-fit tests , *SIMULATION methods in education , *ACCURACY , *RESEARCH funding , *GENOTYPES , *DESCRIPTIVE statistics , *PREDICTION models , *TOPIRAMATE , *LONGITUDINAL method , *CHILDREN - Abstract
Objective: Topiramate, a broad-spectrum antiepileptic drug, exhibits substantial inter-individual variability in both its pharmacokinetics and therapeutic response. The aim of this study was to investigate the influence of patient characteristics and genetic variants on topiramate clearance using population pharmacokinetic (PPK) models in a cohort of Chinese pediatric patients with epilepsy. Method: The PPK model was constructed using a nonlinear mixed-effects modeling approach, utilizing a dataset comprising 236 plasma concentrations of topiramate obtained from 181 pediatric patients with epilepsy. A one-compartment model combined with a proportional residual model was employed to characterize the pharmacokinetics of topiramate. Covariate analysis was performed using forward addition and backward elimination to assess the influence of covariates on the model parameters. The model was thoroughly evaluated through goodness-of-fit analysis, bootstrap, visual predictive checks, and normalized prediction distribution errors. Monte Carlo simulations were utilized to devise topiramate dosing strategies. Result: In the final PPK models of topiramate, body weight, co-administration with oxcarbazepine, and a combined genotype of GKIR1-UGT (GRIK1 rs2832407, UGT2B7 rs7439366, and UGT1A1 rs4148324) were identified as significant covariates affecting the clearance (CL). The clearance was estimated using the formulas CL (L/h) = 0.44 × (BW⁄11.7)0.82 × eOXC for the model without genetic variants and CL (L/h) = 0.49 × (BW⁄11.7)0.81 × eOXC × eGRIK1−UGT for the model incorporating genetic variants. The volume of distribution (Vd) was estimated using the formulas Vd (L) = 6.6 × (BW⁄11.7). The precision of all estimated parameters was acceptable. Furthermore, the model demonstrated good predictability, exhibiting stability and effectiveness in describing the pharmacokinetics of topiramate. Conclusion: The clearance of topiramate in pediatric patients with epilepsy may be subject to the influence of factors such as body weight, co-administration with oxcarbazepine, and genetic polymorphism. In this study, PPK models were developed to better understand and account for these factors, thereby improving the precision and individualization of topiramate therapy in children with epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Drug rash with eosinophilia and systemic symptoms (DRESS): A report of two cases.
- Author
-
Rama, M. C. R., Madhavi, Gottam Bindhu, Mohan, Alladi, Prakash, R. Bhanu, and Devi, B. Vijayalaxmi
- Subjects
- *
DRESS syndrome , *ANTICONVULSANTS - Abstract
Drug Rash with Eosinophilia and Systemic Systems (DRESS) is an idiosyncratic severe cutaneous adverse reaction characterised by a skin rash with systemic involvement. DRESS syndrome can be caused by several drugs. We report two patients who presented with DRESS syndrome caused by anti-epileptic drugs lamotrigine and oxcarbazepine. Based on clinical presentation, laboratory testing and imaging findings, the patients were diagnosed to have DRESS syndrome. In both the patients, offending drugs were stopped and patients were treated with iv corticosteroids, and symptomatic treatment and had recovered. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
- Author
-
Li, Xingmeng, Wei, Shifeng, Wu, Han, Zhang, Qiang, Zhao, Zhigang, Mei, Shenghui, Feng, Weixing, and Wu, Yun
- Subjects
- *
CHILDREN with epilepsy , *CHILDHOOD epilepsy , *CHINESE people , *PHARMACOKINETICS , *CHILD patients , *ANTICONVULSANTS - Abstract
Oxcarbazepine (OXC) is an antiepileptic drug whose efficacy is largely attributed to its monohydroxy derivative metabolite (MHD). Nevertheless, there exists significant inter-individual variability in both the pharmacokinetics and therapeutic response of this drug. The objective of this study is to explore the impact of patients' characteristics and genetic variants on MHD clearance in a population pharmacokinetic (PPK) model of Chinese pediatric patients with epilepsy. The PPK model was developed using a nonlinear mixed effects modeling method based on 231 MHD plasma concentrations obtained from 185 children with epilepsy. The one-compartment model and combined residual model were established to describe the pharmacokinetics of MHD. Forward addition and backward elimination were employed to evaluate the impact of covariates on the model parameters. The model was evaluated using goodness-of-fit, bootstrap, visual predictive checks, and normalized prediction distribution errors. In the two final PPK models, age, estimated glomerular filtration rate (eGFR), and a combined genotype of six variants (rs1045642, rs2032582, rs7668282, rs2396185, rs2304016, rs1128503) were found to significantly reduce inter-individual variability for MHD clearance. The inter-individual clearance equals to 1.38 × (Age/4.74)0.29 × (eGFR/128.66)0.25 × eθABCB-UGT-SCN-INSR for genetic variants included model and 1.30 × (Age/4.74)0.30 × (eGFR/128.66)0.23 for model without genetic variants. The precision of all parameters was deemed acceptable, and the model exhibited good predictability while remaining stable and effective. Conclusion: Age, eGFR, and genotype may play a significant role in MHD clearance in children with epilepsy. The developed PPK models hold potential utility in facilitating oxcarbazepine dose adjustment in pediatric patients. What is Known: • The adjustment of the oxcarbazepine regimen remains difficult due to the considerable inter- and intra-individual variability of oxcarbazepine pharmacokinetics. • Body weight and co-administration with enzyme-inducing antiepileptic drugs emerge as the most influential factors contributing to the pharmacokinetics of MHD. What is New: • A positive correlation was observed between eGFR and the clearance of MHD in pediatric patients with epilepsy. • We explored the influence of genetic polymorphisms on MHD clearance and identified a combined genotype (ABCB-UGT-SCN-INSR) that exhibited a significant association with MHD concentration. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Prescribed antiseizure medication doses and their relation to defined daily doses for achieving seizure freedom in newly diagnosed patients with epilepsy.
- Author
-
Hersi, Hire, Raitanen, Jani, Saarinen, Jukka T., and Peltola, Jukka
- Abstract
Objectives: To investigate the antiseizure medication (ASM) doses required to achieve seizure freedom and their correlation with the World Health Organization's defined daily doses (DDDs) in patients aged 16 years or older with newly diagnosed epilepsy. Methods: The study included 459 patients with a validated diagnosis of new‐onset epilepsy. Patient records were retrospectively analyzed to determine the ASM doses in patients with or without seizure freedom during follow‐up. The DDD of the relevant ASM was then retrieved. Results: The seizure‐freedom rate with first and subsequent ASMs was 88% (404/459 patients) during the follow‐up. The mean prescribed doses (PDDs) and PDD/DDD ratio of the most commonly used ASMs, ie, oxcarbazepine (OXC), carbamazepine (CBZ), and valproic acid (VPA), differed significantly between seizure‐free and non‐seizure‐free status (992 mg and 0.99 vs 1132 mg and 1.13; 547 mg and 0.55 vs 659 mg and 0.66; and 953 mg and 0.64 vs 1260 mg and 0.84, respectively). The effect of the OXC dose as the first failed ASM on the possibility of achieving seizure freedom was significant (Fisher's exact test, p = 0.002). Thirty‐four of 43 patients (79%) in which an OXC dose of ≤900 mg failed became seizure‐free, as compared with 24 of 54 patients (44%) with a failed OXC dose >900 mg. Significance: The present study provides new insights into the doses of the commonly used ASMs such as OXC, CBZ, and VPA that can lead to seizure freedom as monotherapy or as combination therapy. The higher PDD/DDD ratio of OXC (0.99) than that of CBZ or VPA renders a generalized PDD/DDD comparison highly problematic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Design and Evaluation of Sustained Release Bilayer Tablets of Oxcarbazepine.
- Author
-
Ameen, Muath Sheet Mohammed, Ibrahim, Naz Jamal, and Omar, Thamer A.
- Abstract
Objective: The aim of the present study is to modify the release profile of oxcarbazepine by formulating it as a bilayer tablet using direct compression method with dual compression. Methods: In the bilayer system, the immediate release layer was formulated using four types of disintegrants, sodium starch glycolate (SSG), croscarmellose sodium (CCS), cross-linked polyvinylpyrrollidone (crospovidone), and starch. It was found that immediate release layer containing sodium starch glycolate gave faster disintegration time. Therefore, sodium starch glycolate was utilized in the preparation of bilayer tablets in this study. The sustained release layer was prepared utilizing three hydrophobic polymers, two of them are acrylics (Eudragit RS®, Eudragit RL®) and the third one is ethyl cellulose. The prepared bilayer tablets were evaluated for hardness, friability, weight variation, content uniformity, and dissolution profile. Results: The results showed that combination of Eudragit RL® with Eudragit RS® in ratio of 2:1 gave the best modified release profile. Also, using di calcium phosphate as a binder and microcrystalline cellulose (Avicel PH 101) as a diluent resulted in a slower release profile comparing with other formulas. Based on the ʄ2 similarity factor value comparing with reference standard curve, F15, which contains Eudragit RL® and RS® in ratio of 2:1 with mannitol as a diluent and Avicel 102 as a binder, was selected as the best optimized formula. Drug release followed diffusion mechanism rather than erosion mechanism. Furthermore, FTIR spectra showed no possibility of chemical interaction between the drug and polymers, which were used in preparation of bilayer tablet. Stability studies of bilayer tablets under accelerated conditions indicated that the shelf life of the prepared tablets was 3 years and 5 months at 25 °C. However, stability of optimized formula in day light at room temperature revealed that the shelf life of oxcarbazepine is 1 year and 9 months. Conclusion: The results of this study clearly demonstrate that oxcarbazepine can be successfully prepared as a bilayer modified release tablet. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy.
- Author
-
Hersi, Hire, Peltola, Jukka, Raitanen, Jani, and Saarinen, Jukka T.
- Subjects
EPILEPSY ,OLDER patients ,VALPROIC acid ,ANTICONVULSANTS ,AGE groups ,DIAGNOSIS of epilepsy - Abstract
Objective: We evaluate the effect of distinct clinical features on anti-seizure medication (ASM) doses in seizure-free and not seizure-free patients aged ≥16 years with new-onset epilepsy. Materials and methods: This study included 459 patients with a validated diagnosis of epilepsy. The most prescribed ASMs were oxcarbazepine (OXC; n = 307), followed by valproic acid (VPA; n = 115), carbamazepine (CBZ; n = 81), and lamotrigine (LTG; n = 67). The seizure freedom rate with their first or subsequent ASM was 88.0%. A retrospective analysis of patient records was performed to determine any association between doses of ASMs and patient characteristics. Results: The median OXC dose in seizure-free patients aged >60 years was 600mg compared to 900mg in younger patients.When controlling for age but not in an unadjusted model, the median dose of OXC was lower (300mg, p = 0.018) for seizure-free patients compared to non-seizure-free patients, and the median dose of OXC was also 300mg lower among older patients aged >60 years (p < 0.001). The median OXC doses for men aged ≤60 years were 300mg higher than for women aged >60 years (900mg vs. 600mg, p = 0.021). The median dose of VPA was 400mg higher inmen than in women (p<0.001) and 400mg higher in not seizure-free patients compared to seizure-free patients only when adjusting for sex (p < 0.001). Higher median doses for CBZ were registered with FAS compared with FBTCS (difference in median doses of 200mg; p = 0.017). Conclusion: Significant OXC dose differences were detected between age groups, whereas VPA dosing was different in men and women. Moreover, CBZ doses were dependent on some seizure types. These data allow for the individualization of the initial target dosing based on key clinical characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Utility of oxcarbazepine in the treatment of childhood and adolescent psychiatric symptoms
- Author
-
Morrow, Kyle, Young, Keith A, Spencer, Shawn, Medina, Edgar Samuel, Marziale, Michaela A, Sanchez, Alejandro, and Bourgeois, James A
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Pediatric ,Clinical Research ,Brain Disorders ,Mental Health ,Management of diseases and conditions ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,7.3 Management and decision making ,Mental health ,Anticonvulsants ,antipsychotics ,child and adolescent psychiatry ,oxcarbazepine ,Biomedical and clinical sciences - Abstract
The primary aims of this study were to determine if oxcarbazepine is a safely tolerated option for treatment of psychiatric symptoms in children and whether its use facilitates dose modification of other psychotropic medications. A retrospective chart review was completed using data extracted from the electronic medical record of a large outpatient child psychiatry clinic. A total of 507 of 740 children prescribed oxcarbazepine for psychiatric indications for 3 months or more had adequate data to assess clinical responses and medication outcomes. Most patients prescribed oxcarbazepine experienced clinically significant control of irritability/anger, mood stabilization, aggressive outbursts, impulsivity, or anxiety, with over 80% achieving at least maintenance symptom control. In all, 51% and 25% fully discontinued second- or third-generation antipsychotic or antidepressant medication, respectively, after starting oxcarbazepine; 8% discontinued oxcarbazepine for nonresponse, while 9% stopped oxcarbazepine because of emergent side effects. In patients fully discontinuing or reducing the second- or third-generation antipsychotic dose by 50% or more, improvements in body mass index were observed. Oxcarbazepine may prove to be an appropriate alternative to antipsychotic and antidepressant medications for treating psychiatric symptoms in children and adolescents. In particular, it may be a more metabolically neutral psychotropic medication.
- Published
- 2021
41. Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial
- Published
- 2021
42. Hyponatremia-induced worsening of trigeminal neuralgia- When the sodium plays the game.
- Author
-
Ansari, Mohammad Z., Singh, Rashmi, Mohanty, Bijaya, Kumari, Sarita, and Sunder, Ashok
- Abstract
A 78-year-old elderly male who was on treatment for trigeminal neuralgia and hypertension was brought to the emergency with altered sensorium. His vital parameters were within normal limits; however, the arterial blood gas analysis showed severe hyponatremia. He was admitted to the ward, where further workup was carried out and hyponatremia correction started. He had a sudden worsening in his facial pain before he landed in encephalopathy. His medications (oxcarbazepine and chlorthalidone) that could cause hyponatremia were stopped, and judicious correction of hyponatremia was done. His baseline investigations, including a chest roentgenogram and electrocardiogram, were normal. After he regained consciousness, it was noted that the facial pain had regressed significantly despite stopping his first-line drugs. This case of worsening trigeminal neuralgic pain due to hyponatremia responded well to judicious sodium correction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Analysis of clinical features of oxcarbazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis
- Author
-
Qingzi Yan, Xiang Liu, Haibo Lei, Renzhu Liu, and Yixiang Hu
- Subjects
oxcarbazepine ,drug adverse reaction ,Stevens-Johnson syndrome ,toxic epidermal necrolysis ,severe cutaneous adverse reactions ,Medicine (General) ,R5-920 - Abstract
BackgroundStevens-Johnson syndrome (SJS) is considered a hypersensitivity syndrome affecting the skin and mucous membranes. It has been reported that an anticonvulsant drug, oxcarbazepine, may cause Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN). However, the clinical features of oxcarbazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) remain ambiguous. This article aims to explore the clinical features of SJS/TEN.MethodsSystematic searches of several Chinese and English databases were conducted for case reports published on PubMed, EMBASE, Web of Science, MEDLINE, CNKI from January 1, 2007 to March 1, 2023.ResultsA total of seventeen patients (10 males and 7 females) were included in this study, including nine adult patients and eight pediatric patients. The results showed that males seem to have a higher prevalence of SJS/TEN than females, and SJS/TEN usually occurs within 2 weeks after administration of oxcarbazepine (OXC). The main clinical manifestations among the included patients were rashes or maculopapules (17 cases, 100%), fever (11 cases, 64.7%), mucosal lesions (15 cases, 88.2%), conjunctivitis with/without ocular discharge (12 cases, 70.6%), and blisters (12 cases, 70.6%). After stopping OXC or switching to other drugs that treat primary disease as well as treatment with IVIG, glucocorticoid, anti-allergy, and fluid replacement, eight of the included patients recovered completely, and another eight of the included patients reported symptomatic improvement, while the prognosis of one of the included patients was not reported.ConclusionDiverse clinical signs and symptoms of SJS/TEN might result in misinterpretation and delayed diagnosis. It should be identified and treated immediately to avoid significant consequences and potentially jeopardize patients’ lives.
- Published
- 2023
- Full Text
- View/download PDF
44. Role of Mesenchymal Stem Cells (MSCs) individually and with combination of cherry extract against antiepileptic drug induced hepatotoxicity
- Author
-
Asma A AL-Shammary and Mohd Saeed
- Subjects
Mesenchymal Stem Cells ,Cherry extract ,Levetiracetam ,Oxcarbazepine ,Hepatotoxicity ,Histopathology ,Science (General) ,Q1-390 - Abstract
Objectives: Antiepileptic drugs (ADEs) are now used to treat a wide range of neurological problems, although their usage is still restricted due to their side effects, particularly hepatotoxicity. Thus, this study consists of the therapeutic effects of non-conditioned Mesenchymal Stem Cells (MSCs) and the MSCs preconditioned with cherry extract (MSCs CM) on mitigation of liver damage induced by the dual administration of antiepileptic drugs such as Levetiracetam (L) and Oxcarbazepine (O). Methods: The toxicity was induced in male albino rats by the means of the ADEs administration and was examined with the help of different paraments such as biochemical (total protein, albumin, globulin levels, A/G ratio level ALT, and GGTP), Oxidative stress (MDA, NO, and GSH), western blotting assay, immune-histopathology, and histopathological examinations. Results: The results revealed that rats treated with LO showed an increase in the level of ALT, GGTP, MDA, NO, Bax, and the protein expression of AKT and BI3K, caspase 3 level along with a decrease in GSH, total protein, albumin levels as well as, the level of Bcl2. MSCs or MSC CM with cherry extract treatment post antiepileptic drug administration ameliorate these parameters. Our findings suggest that MSCs and MSCs CM could be used in the disparity purpose of dual antiepileptic drugs induced towards normal. Conclusions: Thus, it may be deduced that MSCs and MSC CM can hepatoprotection against ADEs-mediated hepatotoxicity and hence signifying that they could be a used as a valuable natural remedy for treating liver damage caused by drugs.
- Published
- 2023
- Full Text
- View/download PDF
45. Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
- Author
-
Jia-Qin Yi, Sheng Huang, Miao-Juan Wu, Jie-Hui Ma, Li-Juan Huang, Song Liang, and Dan Sun
- Subjects
perampanel ,oxcarbazepine ,newly diagnosed focal epilepsy ,monotherapy ,anti-seizure medications ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2023
- Full Text
- View/download PDF
46. Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy
- Author
-
Hire Hersi, Jukka Peltola, Jani Raitanen, and Jukka T. Saarinen
- Subjects
antiseizure medication ,newly diagnosed epilepsy ,seizure freedom ,treatment outcomes ,oxcarbazepine ,valproic acid ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
ObjectiveWe evaluate the effect of distinct clinical features on anti-seizure medication (ASM) doses in seizure-free and not seizure-free patients aged ≥16 years with new-onset epilepsy.Materials and methodsThis study included 459 patients with a validated diagnosis of epilepsy. The most prescribed ASMs were oxcarbazepine (OXC; n = 307), followed by valproic acid (VPA; n = 115), carbamazepine (CBZ; n = 81), and lamotrigine (LTG; n = 67). The seizure freedom rate with their first or subsequent ASM was 88.0%. A retrospective analysis of patient records was performed to determine any association between doses of ASMs and patient characteristics.ResultsThe median OXC dose in seizure-free patients aged >60 years was 600 mg compared to 900 mg in younger patients. When controlling for age but not in an unadjusted model, the median dose of OXC was lower (300 mg, p = 0.018) for seizure-free patients compared to non-seizure-free patients, and the median dose of OXC was also 300 mg lower among older patients aged >60 years (p < 0.001). The median OXC doses for men aged ≤60 years were 300 mg higher than for women aged >60 years (900 mg vs. 600 mg, p = 0.021). The median dose of VPA was 400 mg higher in men than in women (p < 0.001) and 400 mg higher in not seizure-free patients compared to seizure-free patients only when adjusting for sex (p < 0.001). Higher median doses for CBZ were registered with FAS compared with FBTCS (difference in median doses of 200 mg; p = 0.017).ConclusionSignificant OXC dose differences were detected between age groups, whereas VPA dosing was different in men and women. Moreover, CBZ doses were dependent on some seizure types. These data allow for the individualization of the initial target dosing based on key clinical characteristics.
- Published
- 2023
- Full Text
- View/download PDF
47. Gabapentin monotherapy for epilepsy: A review.
- Author
-
Ziganshina, Liliya Eugenevna, Abakumova, Tatyana, and Hoyle, Charles H.V.
- Subjects
- *
DIAGNOSIS of epilepsy , *ANTICONVULSANTS , *ONLINE information services , *RELATIVE medical risk , *LAMOTRIGINE , *CARBAMAZEPINE , *MEDICAL information storage & retrieval systems , *CONFIDENCE intervals , *META-analysis , *EPILEPSY , *SYSTEMATIC reviews , *RESEARCH funding , *MEDLINE , *GABAPENTIN , *TOPIRAMATE - Abstract
BACKGROUND: Epilepsy is one of the most common chronic neurological disorders, affecting more than 50 million people globally. In this review we summarised the evidence from randomised controlled trials of gabapentin used as monotherapy for the treatment of focal epilepsy, both newly diagnosed and drug-resistant, with or without secondary generalisation. OBJECTIVE: To assess the effects of gabapentin monotherapy for people with epileptic focal seizures with and without secondary generalisation. METHODS: We searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 24 February 2020) on 25 February 2020. CRS Web includes randomised or quasi-randomised controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, the Cochrane Central Register of Controlled Trials (CENTRA), and the specialised registers of Cochrane Review Groups including the Cochrane Epilepsy Group. We also searched several Russian databases, reference lists of relevant studies, ongoing trials registers, conference proceedings, and we contacted trial authors. RESULTS: We found five randomised controlled trials (3167 participants) comparing gabapentin to other antiepileptic drugs (AEDs) and differing doses of gabapentin as monotherapy for newly diagnosed focal epilepsy and drug- resistant focal epilepsy with or without secondary generalisation. Two review authors independently applied the inclusion criteria, assessed trial quality, risk of bias, and extracted data. We used the GRADE approach to assess the certainty of evidence and present seven patient-important outcomes in the "Summary of findings" tables. The quality of evidence was very low to moderate due to poor reporting quality, poor trial design, and other risks of bias, such as selective presentation of findings and potential heavy industry input. Better quality research may change our certainty in the effect estimates. None of the included trials reported on the number of people with 50% or greater reduction in seizures and time to withdrawal (retention time) in an extractable way. Gabapentin-treated participants were more likely to withdraw from treatment for any cause (285/539) than those treated with lamotrigine, oxcarbazepine, or topiramate pooled together (695/1317) (RR 1.13, 95% CI 1.02 to 1.25; 3 studies, 1856 participants; moderate-certainty evidence), but not carbamazepine. Fewer people treated with gabapentin withdrew from treatment owing to adverse events (190/525) than those treated with carbamazepine, oxcarbazepine, or topiramate (479/1238), (RR 0.79, 95% CI 0.69 to 0.91; 1763 participants, 3 studies; moderate-certainty evidence), but not lamotrigine. CONCLUSION: Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate). Compared to carbamazepine, gabapentin was probably better in retaining people in studies and preventing withdrawals due to adverse events. The most common side effects associated with gabapentin were ataxia (poor co-ordination and unsteady gait), dizziness, fatigue, and drowsiness. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Theoretical insights into the degradation mechanisms, kinetics and eco-toxicity of oxcarbazepine initiated by OH radicals in aqueous environments.
- Author
-
Sun, Yanhui, Li, Ming, Hadizadeh, Mohammad Hassan, Liu, Lin, and Xu, Fei
- Subjects
- *
CHRONIC toxicity testing , *DENSITY functional theory , *METHYLENE group , *HYGIENE products , *GREEN algae , *BRANCHING ratios - Abstract
• The OH-initiated degradation mechanisms of OXC in AOPs have been performed. • The OH-addition occurring in the C8 position of benzene ring is more favorable. • Total rate constant of OXC with OH radicals is 9.47 × 109 (mol/L)−1sec−1 at 298 K. • Continuous hydroxylation could decrease the eco-toxicity of OXC. As an anticonvulsant, oxcarbazepine (OXC) has attracted considerable attention for its potential threat to aquatic organisms. Density functional theory has been used to study the mechanisms and kinetics of OXC degradation initiated by OH radicals in aqueous environment. A total of fourteen OH-addition pathways were investigated, and the addition to the C8 position of the right benzene ring was the most vulnerable pathway, resulting in the intermediate IM8. The H-abstraction reactions initiated by OH radicals were also explored, where the extraction site of the methylene group (C14) on the seven-member carbon heterocyclic ring was found to be the optimal path. The calculations show that the total rate constant of OXC with OH radicals is 9.47 × 109 (mol/L)−1sec−1, and the half-life time is 7.32 s at 298 K with the [·OH] of 10−11 mol/L. Moreover, the branch ratio values revealed that OH-addition (89.58%) shows more advantageous than H-abstraction (10.42%). To further understand the potential eco-toxicity of OXC and its transformation products to aquatic organisms, acute toxicity and chronic toxicity were evaluated using ECOSAR software. The toxicity assessment revealed that most degradation products such as OXC-2OH, OXC-4OH, OXC-1O-1OOH, and OXC-1OH' are innoxious to fish and daphnia. Conversely, green algae are more sensitive to these compounds. This study can provide an extensive investigation into the degradation of OXC by OH radicals and enrich the understanding of the aquatic oxidation processes of pharmaceuticals and personal care products (PPCPs). [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Thermoresponsive Gel-loaded Oxcarbazepine Nanosystems for Nose- To-Brain Delivery: Enhanced Antiepileptic Activity in Rats.
- Author
-
Abou-Taleb, Basant A. and El-Ganainy, Samar O.
- Subjects
- *
INTRANASAL administration , *ZETA potential , *RATS , *SEIZURES (Medicine) , *ANTICONVULSANTS , *PHENOBARBITAL - Abstract
Background: Oxcarbazepine (OXC) is a frequently prescribed antiepileptic drug for managing focal and generalized seizures. Its therapeutic benefits are limited by its dose-dependent side effects. Nose-to-brain delivery is a novel route for improving the efficacy of antiepileptics. Drug encapsulation in mucoadhesive nanoparticles offers even more advantages for the nasal route. Objective: The study aimed to develop oxcarbazepine-loaded chitosan nanoparticles (OXC-NP) added to a mucoadhesive thermo-reversible gel for intranasal delivery and enhancement of antiepileptic activity. Methods: The formulation was optimized based on entrapment efficiency, polydispersity index, particle size, zeta potential, and in vitro release analysis. The therapeutic efficacy of OXC-NP was assessed in an epileptic rat model and compared to intranasal OXC and oral OXC. Results: The optimized OXC-NPs with chitosan exhibited particle size, zeta potential, and entrapment efficiency of 189 nm, + 31.4 mV ± 2.5 and 97.6% ± 0.14, respectively. The release of OXC was prolonged, reaching 47.1% after 6 h and 55% after 24 h. Enhanced antiepileptic activity of OXC-NP was manifested as decreased seizure score and prolonged survival. Halting of hippocampal TNF-α and IL-6 together with upregulated IL-10 could explain its anti-inflammatory mechanisms. Conclusions: Intranasal OXC-NP-loaded in situ gel represents a promising formulation for enhanced antiepileptic potential achieved at low drug concentrations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. 5 种常用抗癫痫药物的临床使用情况及其血清浓度水平的分析及意义.
- Author
-
张 奇, 陆雯琪, 冯文坤, 叶康保, 汪世靖, 吴君霞, 王 训, and 胡文彬
- Abstract
Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.